Communiqués NLS PHARPAR

Actions

NLSP

CH1384053976

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/07/2026			Varia. 5j.	Varia. 1 janv.
3,850 ^USD	+5,19 %		+3,39 %	-49,48 %

30/10/25	NLS Pharmaceutics Ltd. et Kadimastem Ltd. annoncent la finalisation de leur fusion	RE
30/10/25	NLS Pharmaceutics Ltd. et Aexon Labs annoncent l'extension de leur plateforme DOXA avec la série AEX-6xx	CI

Communiqués

17/11	NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute	PR
30/10/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger	PR
30/10/25	NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs	PR
22/05/25	NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting	AQ
31/03/25	NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement	AQ
17/02/25	NLS Pharmaceutics : NLSP) Core Investment 13022025	PU
03/02/25	Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics	AQ
31/01/25	NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting	AQ
09/01/25	NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting	AQ
30/12/24	NLS Pharmaceutics : The proposed transaction will create a Nasdaq traded, biotechnology company with product candidates in advanced stages of clinical development and a focus on advancing its allogeneic cell therapy platform Form 6 K	PU
23/12/24	NLS Pharmaceutics : Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Form 6 K	PU
19/12/24	NLS Pharmaceutics : Amendment to Current Report by Foreign Issuer (Form 6-K/A)	PU
19/12/24	NLS Pharmaceutics : and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment Form 6 K	PU
17/12/24	NLS Pharmaceutics : Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Form 6 K	PU
12/12/24	NLS Pharmaceutics CEO Issues Letter to Shareholders	AQ
11/12/24	NLS Pharmaceutics : CEO Issues Letter to Shareholders Form 6 K	PU
04/12/24	NLS Pharmaceutics : SECURITIES PURCHASE AGREEMENT Form 6 K	PU
04/12/24	NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market	PR
03/12/24	NLS Pharmaceutics : Announces Promising Preclinical Data for First in Class Non Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders Form 6 K	PU
19/11/24	NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists in Narcolepsy and Neurological Disorders	AQ
18/11/24	NLS Pharmaceutics : Highlights Innovative Preclinical Program for First in Class Non Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders Form 6 K	PU
12/11/24	NLS Pharmaceutics : Kadimastem Ltd. Financial Statements as of December 31, 2023 Form 6 K	PU
08/11/24	NLS Pharmaceutics : Extraordinary Shareholders’ Meeting Results Form 6 K	PU
06/11/24	NLS Pharmaceutics : Notice of Meeting and Proxy Card for the Extraordinary Shareholders’ Meeting to be held on November 8, 2024 Form 6 K	PU
05/11/24	NLS Pharmaceutics : AGREEMENT OF MERGER AND PLAN OF REORGANIZATION Form 6 K	PU